InfuSystem Holdings continues to diversify, focus on profitable growth

ROCHESTER HILLS, Mich. – InfuSystem Holdings reported net revenues of $36.9 million for the second quarter, a 2.6% increase compared to the prior-year period. Patient Services net revenue was $24.8 million, a 15% increase; and Device Solutions net revenue was $12.1 million, a 16% increase. Other financial results:

• Gross profit was $21.4 million, an increase of 8% vs. prior year
• Gross margin was 58%, an increase of 3% vs. prior year
• Net income was $3.2 million, or $0.15 per diluted share vs. prior year net income of $2.6 million, or $0.12 per diluted share
• Adjusted earnings before interest, income taxes, depreciation, and amortization (non-GAAP) was $8.6 million, an increase of 8% vs. prior year
• Adjusted EBITDA margin was 23.4%, an increase of 1.1% vs. prior year

"We delivered another strong quarter, achieving record revenue of $36.9 million and growing Adjusted EBITDA by 7.6%,” said Carrie Lachance, CEO. “Our Oncology business continued its steady momentum, surpassing $20 million in quarterly revenue for the first time, while Wound Care delivered exceptional growth driven by strong adoption of our new lymphedema compression therapy offerings. As our business continues to diversify, we remain focused on pursuing profitable growth while driving ever greater efficiencies."

InfuSystem is reaffirming annual net revenue guidance for the full year 2026. After adjusting for the impact of the reduced revenue related to the GE Healthcare contract restructuring, pro-forma net revenue growth is estimated to be between 6% to 8% for 2026. The company is also continuing to forecast adjusted EBITDA margin (non-GAAP) to be in the mid to low 20%s. This includes the implementation expenses for the company's upgraded information technology systems, which went online on March 1, 2026.

• Related: InfuSystem makes advances, building on tech investments.